Australia's First
TB-500 & BPC-157
Subcutaneous Pen



What is TB-500 + BPC-157?

TB-500 + BPC-157 is a compounded peptide combination that brings together two research peptides often discussed in relation to tissue recovery, repair signalling, and soft tissue support.

TB-500 is a synthetic peptide fragment associated with thymosin beta-4 activity and is generally discussed in research in the context of tissue repair, cell migration, and recovery signalling.

BPC-157 is a synthetic peptide studied in pre-clinical settings for its interaction with healing pathways involving tendon, ligament, muscle, connective tissue, and vascular signalling. Available evidence for both remains limited, with much of the literature consisting of pre-clinical work rather than broad, high-quality human therapeutic evidence.

Rather than being described as direct stimulants, these peptides are generally considered in the context of signalling, repair coordination, and the regulation of recovery-related pathways. When paired together, they are usually considered as a broader soft tissue recovery combination rather than as a product aimed at one isolated structure or outcome.

In Australia, these substances are not registered therapeutic goods on the ARTG for general therapeutic use. Where supplied, they are generally handled within prescription and compounding frameworks following individual clinical assessment.

What TB-500 + BPC-157 is Being Studied For?

Research involving TB-500 and BPC-157 has explored their role across pathways associated with tissue recovery and repair.

Areas of investigation include:
soft tissue recovery signalling
tendon and ligament healing models
muscle and connective tissue repair
angiogenic and vascular signalling
fibroblast activity and extracellular matrix support
tissue response following mechanical or physiological stress
broader recovery models involving wound healing and structural repair

Much of this research focuses on how healing and recovery processes are organised and supported under stress or injury conditions, rather than targeting a single narrow mechanism. Current evidence is still evolving and is strongest in pre-clinical settings, with broader human application remaining uncertain.

How It's Dispensed?

When prescribed, TB-500 + BPC-157 is compounded by an Australian-registered pharmacy and dispensed under pharmacist supervision.

TB-500 Concentration: 3 mg/mL
BPC-157 Concentration: 2 mg/mL
Total Volume: 3 mL
Total Content: 9 mg TB-500 + 6 mg BPC-157 per pen
Standard Dose: 30IU as directed
Route: Subcutaneous injection
Format: Pre-filled multi-dose pen


Products are prepared in accordance with pharmacy compounding standards, with sterility and stability managed within controlled laboratory environments. Where required, temperature-controlled packaging is used during transport to maintain product integrity. TGA guidance makes clear that compounded medicines must still meet applicable quality standards, even where they are supplied outside ARTG registration pathways.

Storage & Handling

Keep refrigerated as directed by the dispensing pharmacy.
Do not freeze or expose to excessive heat.
If ice packs melt during transit, product integrity remains unaffected within the advised shipping window.
Always follow the storage and handling guidance supplied with your prescription.

Usage & Administration

Administration is determined by the prescribing clinician based on individual context and requirements.

Route: Subcutaneous injection
Injection site: Abdomen or outer thigh
Dose: As prescribed according to concentration and protocol
Frequency: Often once daily or as otherwise directed
Cycle: Structured short-term use aligned with recovery demands


Administration should only occur following appropriate instruction and clinical clearance.

Injection sites should be rotated to maintain tissue integrity, and all equipment should be used and disposed of according to clinical guidance.

Safety & Precautions

Schedule 4 (Prescription-Only Medicines) must be prescribed and supervised by a registered healthcare professional.
Disclose all medical conditions, allergies, and concurrent medications before treatment.
Not recommended during pregnancy or breastfeeding unless specifically approved by a clinician.
Report any irritation or unexpected response to your prescriber or pharmacist.
Always store and administer as directed by the dispensing pharmacy.

Research Context

TB-500 + BPC-157 remains an active area of investigation within peptide and recovery research.

BPC-157 has been studied in pre-clinical models involving tendon, ligament, muscle, and wound healing pathways, while TB-500 has been discussed in relation to tissue recovery and regenerative signalling. However, these areas remain investigational, and long-term safety, optimal dosing, and consistent clinical outcomes have not been established across broad populations.

TB-500 has also been noted by Australian regulatory material as not being marketed for human therapeutic use, and regulatory scrutiny around peptide advertising in Australia has been significant.

Disclaimer

This information is provided for educational purposes only and does not constitute medical advice.

TB-500 and BPC-157 are not registered therapeutic goods with the Therapeutic Goods Administration (TGA) for general therapeutic use in Australia. Where supplied, they are provided under prescription through a compounding pharmacy following individual clinical assessment. No therapeutic claims are made.

Use only under consultation and prescription from a registered healthcare professional.

Mobile IV Drip

TB-500 and BPC-157 Australia

Prescription TB-500 and BPC-157

Australian Compounded Peptides

Australian Compounded Prescription Peptides

TB-500 BPC-157 Pen

Wolverine Peptide

Wilverine Stack

Combined Recovery Peptide Pen

TB-500 and BPC-157 Subcutaneous Pen

Broad Tissue Recovery Support

Soft Tissue Recovery Peptide

Repair Pen

Repair TB-500 and BPC-157

ExclusIV Disclaimer

By continuing, you acknowledge and agree to the following terms and conditions of ExclusIV by Mobile IV Drip:

1. Elective Wellness Services
All IV infusions and subcutaneous products offered through Mobile IV Drip are elective wellness services. They are not prescribed or promoted as medically necessary treatments and are designed to support general wellness and vitality.

2. No Public Advertising
The information displayed in this section is provided privately on request and does not constitute public advertising.

3. No Medical or Therapeutic Claims
No statements here should be interpreted as claims of therapeutic benefit. Services and compounded formulations are not a substitute for professional medical advice, prescribed medication, or conventional treatment.

4. Practitioner Review Required
Before any compounded or prescription-only product is supplied, clients are required to complete medical intake and be reviewed by an authorised prescriber and/or nurse practitioner, and obtain a prescription where required.

5. Pricing
Pricing shown is indicative only and may change following clinical assessment, prescription requirements, or compounding variables. Final costs are confirmed after prescriber approval.

6. Voluntary Request
You confirm you are voluntarily requesting this information for personal education, and that access does not guarantee suitability for every option listed.

7. Privacy
Any information you provide may be used to communicate about consultations, prescriptions or updates, with opt-out available.

By selecting “I want ExclusIV access”, you confirm you have read and understood the above.